Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Pietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, Evangelista Sagnelli, Massimo Fasano, Vito Di Marco, Sara Boninsegna, Patrizia Farci, Silvia Fargion, Tiziana Giuberti, Claudio Iannacone, Loredana Regep, Benedetta Massetto, Floriana Facchetti, Massimo Colombo

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population. Methods: 128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 mg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 mg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA

Original languageEnglish
Pages (from-to)290-298
Number of pages9
JournalGut
Volume62
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Genotype
Hepatitis B virus
Lamivudine
Standard of Care
Alanine Transaminase
Therapeutics
DNA
Population

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. / Lampertico, Pietro; Viganò, Mauro; Di Costanzo, Giovan Giuseppe; Sagnelli, Evangelista; Fasano, Massimo; Di Marco, Vito; Boninsegna, Sara; Farci, Patrizia; Fargion, Silvia; Giuberti, Tiziana; Iannacone, Claudio; Regep, Loredana; Massetto, Benedetta; Facchetti, Floriana; Colombo, Massimo.

In: Gut, Vol. 62, No. 2, 02.2013, p. 290-298.

Research output: Contribution to journalArticle

Lampertico, P, Viganò, M, Di Costanzo, GG, Sagnelli, E, Fasano, M, Di Marco, V, Boninsegna, S, Farci, P, Fargion, S, Giuberti, T, Iannacone, C, Regep, L, Massetto, B, Facchetti, F & Colombo, M 2013, 'Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B', Gut, vol. 62, no. 2, pp. 290-298. https://doi.org/10.1136/gutjnl-2011-301430
Lampertico, Pietro ; Viganò, Mauro ; Di Costanzo, Giovan Giuseppe ; Sagnelli, Evangelista ; Fasano, Massimo ; Di Marco, Vito ; Boninsegna, Sara ; Farci, Patrizia ; Fargion, Silvia ; Giuberti, Tiziana ; Iannacone, Claudio ; Regep, Loredana ; Massetto, Benedetta ; Facchetti, Floriana ; Colombo, Massimo. / Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. In: Gut. 2013 ; Vol. 62, No. 2. pp. 290-298.
@article{de293f50e2a74bffa9aba8dc82f58714,
title = "Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B",
abstract = "Objective: Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population. Methods: 128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 mg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 mg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA",
author = "Pietro Lampertico and Mauro Vigan{\`o} and {Di Costanzo}, {Giovan Giuseppe} and Evangelista Sagnelli and Massimo Fasano and {Di Marco}, Vito and Sara Boninsegna and Patrizia Farci and Silvia Fargion and Tiziana Giuberti and Claudio Iannacone and Loredana Regep and Benedetta Massetto and Floriana Facchetti and Massimo Colombo",
year = "2013",
month = "2",
doi = "10.1136/gutjnl-2011-301430",
language = "English",
volume = "62",
pages = "290--298",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

AU - Lampertico, Pietro

AU - Viganò, Mauro

AU - Di Costanzo, Giovan Giuseppe

AU - Sagnelli, Evangelista

AU - Fasano, Massimo

AU - Di Marco, Vito

AU - Boninsegna, Sara

AU - Farci, Patrizia

AU - Fargion, Silvia

AU - Giuberti, Tiziana

AU - Iannacone, Claudio

AU - Regep, Loredana

AU - Massetto, Benedetta

AU - Facchetti, Floriana

AU - Colombo, Massimo

PY - 2013/2

Y1 - 2013/2

N2 - Objective: Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population. Methods: 128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 mg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 mg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA

AB - Objective: Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population. Methods: 128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 mg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 mg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA

UR - http://www.scopus.com/inward/record.url?scp=84872079300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872079300&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2011-301430

DO - 10.1136/gutjnl-2011-301430

M3 - Article

VL - 62

SP - 290

EP - 298

JO - Gut

JF - Gut

SN - 0017-5749

IS - 2

ER -